Full-Time

Key Account Manager Fixed Term Contract

Confirmed live in the last 24 hours

Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical

1,001-5,000 employees

Develops therapies for rare genetic diseases

No salary listed

Mid, Senior

Birmingham, UK

Category
Strategic Account Management
Sales & Account Management
Required Skills
Sales
Requirements
  • University degree in Medicine/Biology/Chemistry/Pharmacy or equivalent degree
  • 3- 5 years of sales experience in secondary care with a proven success record in product launches in highly specialized therapeutic areas
  • Experienced in marketing and sales of Orphan Drugs
  • Experience in key opinion leader engagement
  • Experience in organization of educational events
  • Analytical skills
  • Thorough knowledge of local industry code of conduct and relevant legislation
  • Good understanding of national health care system and decision-making pathways in hospital and regional ecosystems
Responsibilities
  • Independent continuous analysis of market potential, treatment paradigms and referral patterns in the assigned territory
  • Developing, executing and presenting account plans for key accounts in the territory
  • Analzying effectiveness of commercial tactics
  • Establishing sustainable, mutually beneficial relations to opinion leaders and other key stakeholders in the territory, leveraging personal contacts.
  • Optimizing patient care by aligning decision makers involved in relevant decisions (e.g. specialists, nurses, pharmacists, payers)
  • Developing and executing strategies to identify undiagnosed or misdiagnosed patients
  • Engage in regular exchange with peers to share best practices
  • Monitor changes in the health care system to identify new business opportunities
  • Support market access on a local level (regions and hospitals) to ensure patients have sustainable access to pharmaceutical innovation
Desired Qualifications
  • Experience with national reimbursement system and regional payers
  • Established contacts with opinion leaders in metabolic medicine
  • Experienced in Sales of Orphan Drugs and highly innovative products
Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical

View

Ultragenyx Pharmaceutical develops and commercializes therapies specifically for rare and ultra-rare genetic diseases. The company focuses on creating treatments for conditions that currently have few or no options available. Their approach involves identifying unmet medical needs in the rare disease sector and advancing multiple clinical-stage programs simultaneously, which allows them to target various rare diseases at once. Ultragenyx has received FDA approval for treatments like burosumab for Tumor Induced Osteomalacia and UX007 for Long-chain Fatty Acid Oxidation Disorders, generating revenue through these approved therapies. Unlike many competitors, Ultragenyx is dedicated to ensuring a consistent supply of its medicines, even during challenges like the COVID-19 pandemic. The company's goal is to transform scientific research into effective treatments for patients with rare genetic diseases, emphasizing patient care and support.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Novato, California

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • GTX-102 in Phase III trials could lead Ultragenyx in Angelman syndrome treatment.
  • NICE's recommendation of Evkeeza boosts Ultragenyx's market presence in the UK.
  • Setrusumab development opens new therapeutic avenues for bone formation treatments.

What critics are saying

  • Intense competition in Angelman syndrome treatment may impact Ultragenyx's market share.
  • Setrusumab's success is uncertain, facing potential clinical and regulatory challenges.
  • Delays in NICE's recommendation for Evkeeza could affect Ultragenyx's revenue.

What makes Ultragenyx Pharmaceutical unique

  • Ultragenyx focuses on rare and ultra-rare genetic diseases with limited treatment options.
  • The company has a diversified product pipeline addressing multiple rare diseases simultaneously.
  • Ultragenyx's commitment to uninterrupted medicine supply ensures consistent patient treatment.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

Volunteer Days

Stock Options

Company Equity

Wellness Program

Professional Development Budget

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
BioSpace
Mar 17th, 2025
Opinion: Angelman Syndrome Race Heats Up Among Ionis, Ultragenyx And Neuren

Several companies are working on new investigational treatments for Angelman syndrome, a rare genetic disorder that affects the nervous system and causes developmental delays, intellectual disability, seizures and speech impairment. Ionis and Ultragenyx are competing to bring investigational antisense oligonucleotide treatments to the market, while Neuren is betting on a synthetic peptide that can be delivered orally. It’s a tight race in a disease space with a high unmet need.Affecting 500,000 to 1 million patients worldwide, Angelman syndrome has no approved disease-modifying treatments. Although antiseizure medication is available, these drugs do not address the root cause, a genetic mutation in the UBE3A gene on chromosome 15. In Angelman syndrome, only the copy of the UBE3A gene inherited from the mother is functional, while the father’s allele is mutated.Both Ionis and Ultragenyx are currently in Phase III trials with their oligonucleotides, called ION582 and GTX-102, respectively. Meanwhile, Neuren is conducting a mid-stage trial on NNZ-2591, a twice-daily oral solution consisting of a synthetic peptide that modulates acetylcholine neurotransmission.Ionis’ ION582 is an investigational intrathecal injection that targets a long noncoding RNA to increase expression of the UBE3A protein in neurons

Arabic Week
Feb 20th, 2025
Global ANGPTL3-lowering therapy market is expected to reach US$ 785.21 million by 2031

Recent Developments In January 2024, Ultragenyx Pharmaceutical Inc. announced that the National Institute for Health and Care Excellence (NICE) has released a final draft guidance recommending Evkeeza (evinacumab) for use within NHS England.

GlobeNewswire
Jan 6th, 2025
Ultragenyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

NOVATO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) - Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 10:30 AM PT.

Stat News
Jan 6th, 2025
The biotech scorecard for the first quarter: 16 stock-moving events to watch

Ultragenyx is developing an antibody treatment for the disease called setrusumab that works by blocking sclerostin, a protein that inhibits bone formation.

TipRanks
Nov 5th, 2024
Ultragenyx Reports Strong Q3 Growth and Milestones

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company dedicated to developing novel therapies for rare and ultra-rare genetic diseases, with a focus on advancing treatments where there are unmet medical needs.